Search results for "Ladder"

showing 10 items of 674 documents

Surgery in rhabdomyosarcoma of the bladder, prostate and vagina

1995

The treatment of bladder and prostate rhabdomyosarcoma (RMS) is highly controversial. Aside from chemotherapy, treatment modalities include conservative surgery, radical surgery, and pre-, intra-, or postoperative irradiation. Between 1968 and 1993, 78 children with RMS were treated at our institution. In all, 22 tumors were located in the urogenital tract (bladder/prostate, 13; paratesticular, 5; vaginal, 2; others, 2). Altogether, 6 patients had stage II disease; 7, stage III disease; and 2, stage IV disease. All 15 patients with RMS of the bladder, prostate, or vagina received chemotherapy, and 4 had additional radiotherapy. Surgery was also done in 10 patients; parents refused an operat…

Malemedicine.medical_specialtyVaginal NeoplasmsAdolescentUrologymedicine.medical_treatmentProstate RhabdomyosarcomaVaginal diseaseProstateAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomamedicineHumansRadical surgeryStage (cooking)ChildRhabdomyosarcomaRetrospective StudiesUrinary bladderbusiness.industryInfantProstatic Neoplasmsmedicine.diseaseSurgeryRadiation therapyTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsChild PreschoolFemalebusinessFollow-Up StudiesWorld Journal of Urology
researchProduct

Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery

2003

Rhabdomyosarcoma of pelvic organs is not common enough for many people to develop large series. However, the authors from Mainz retrospectively analysed 107 children with this condition, and suggest that primary chemotherapy followed by radical surgery yields excellent cure rates. OBJECTIVE To retrospectively analyse the outcome of children with rhabdomyosarcoma (RMS) of the bladder, prostate or vagina who were treated with chemotherapy, with or without radical surgery or additional radiotherapy, at our institution since 1968. PATIENTS AND METHODS From a total of 107 children with RMS seen between 1968 and December 2001, 22 (mean age 5.9, range 0.5–18) had RMS of bladder/prostate or vagina.…

Malemedicine.medical_specialtyVaginal NeoplasmsAdolescentUrologymedicine.medical_treatmentUrologyUrinary DiversionCystectomyAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomamedicineHumansRadical surgeryChildRhabdomyosarcomaRetrospective StudiesProstatectomyIfosfamideUrinary bladderbusiness.industryUrinary diversionInfantProstatic Neoplasmsmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsBladder augmentationChild PreschoolFemalePouchbusinessContinent Urinary DiversionFollow-Up Studiesmedicine.drugBJU International
researchProduct

A Nomogram to Characterize the Severity of Detrusor Overactivity during the Ice Water Test: Description of the Method and Proof of Concept

2017

<b><i>Aims:</i></b> To develop a nomogram with severity categories for detrusor overactivity (DO). <b><i>Methods:</i></b> By conducting ice water tests (IWT) in 55 patients with Parkinson’s disease, we identified criteria to describe characteristics of the detrusor pressure curves: (1) a gradient of Δ<i>pdet</i> over Δt at the maximum detrusor pressure and (2) the area under the curve. In a nomogram, 10 severity categories of DO were established: 1 and 2 were assigned to group A (mild), 3 and 4 to group B (moderate) and 5–10 to group C (severe). <b><i>Results:</i></b> In the nomogram, negative IWT (20) appea…

Malemedicine.medical_specialtygenetic structuresUrologyUrinary Bladder030232 urology & nephrologyUrologyurologic and male genital diseasesProof of Concept Study03 medical and health sciences0302 clinical medicinemedicineHumansUrinary Bladder NeurogenicAgedUrinary Bladder Overactivebusiness.industryArea under the curveReproducibility of ResultsParkinson DiseaseMiddle AgedNomogramIce waterNomogramsUrodynamicsAdministration IntravesicalUrinary Incontinence030220 oncology & carcinogenesisDetrusor pressureFemalebusinessUrologia Internationalis
researchProduct

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer

2016

Abstract Background The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n = 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients no…

Malemedicine.medical_specialtymedicine.drug_classUrology030232 urology & nephrologyLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansAntiplateletStage (cooking)Macroscopic hematuriaAnticoagulant; Antiplatelet; Bladder cancer; Emergency room; Hematuria; Non-muscle invasive bladder cancerEarly Detection of CancerRetrospective StudiesHematuriaAgedNeoplasm StagingBladder cancerbusiness.industryPlatelet Aggregation InhibitorAnticoagulantBladder cancerAnticoagulantAnticoagulantsRetrospective cohort studyEmergency roomOdds ratioMiddle Agedmedicine.diseaseSurgeryUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmPlatelet aggregation inhibitorFemalebusinessNon-muscle invasive bladder cancerPlatelet Aggregation InhibitorsHuman
researchProduct

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective Internationa…

2017

IF 3.156; International audience; Background: Radical cystectomy (RC) and radiochemotherapy (RCT) are curative options for muscle-invasive bladder cancer (MIBC). Optimal treatment strategy remains unclear in elderly patients.Material and methods: Patients aged 80 years old and above with T2-T4aN0-2M0-Mx MIBC were identified in the Retrospective International Study of Cancers of the Urothelial Tract (RISC) database. Patients treated with RC were compared with those treated with RCT. The impact of surgery on overall survival (OS) was assessed using a Cox proportional hazard model. Progression included locoregional and metastatic relapse and was considered a time-dependent variable.Results: Be…

Malemedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyUrology[SDV.CAN]Life Sciences [q-bio]/CancerKaplan-Meier EstimateCystectomyBladder preservationDisease-Free Survivallaw.inventionCystectomy03 medical and health sciences0302 clinical medicineRandomized controlled triallawCarcinomamedicineHumansRadiology Nuclear Medicine and imagingProportional Hazards ModelsRetrospective StudiesAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryProportional hazards modelMuscle invasiveRetrospective cohort studyHematologyGeneral MedicineChemoradiotherapymedicine.disease3. Good healthSurgeryTreatment OutcomeOncologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisFemalebusinessActa oncologica (Stockholm, Sweden)
researchProduct

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer tre…

2015

Objectives To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette–Gu erin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical out…

Malemedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineImmunologicRetrospective Studiehigh gradere-TURHazard ratioMiddle Agedmedicine.anatomical_structureAdministration IntravesicalTreatment Outcome030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortUrinary Bladder NeoplasmBCG VaccineUrologic Surgical Proceduresbladder cancerFemaleHumanReoperationmedicine.medical_specialtyrecurrenceUrologyUrologyT1G3CystectomyArticleCystectomy03 medical and health sciencesbladder cancer; high grade; progression; re-TUR; recurrence; T1G3; UrologyAdjuvants ImmunologicUrethramedicineHumansAdjuvantsT1G3; bladder cancer; high grade; progression; re-TUR; recurrenceRetrospective StudiesAgedNeoplasm StagingBladder cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseSurgerybladder cancer; high grade; progression; re-TUR; recurrence; T1G3; Adjuvants Immunologic; Aged; BCG Vaccine; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Reoperation; Retrospective Studies; Treatment Outcome; Urethra; Urinary Bladder Neoplasms; UrologyUrethraUrinary Bladder NeoplasmsprogressionNeoplasm GradingbusinessBCG vaccine
researchProduct

Neuromodulation of the superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?

2009

Abstract Background The aim of this study is to report on the impact of neuromodulation to the superior hypogastric plexus in patients with bladder atonia secondary to pelvic surgery. Methods In 4 consecutive patients with bladder atonia secondary to pelvic surgery, we performed a laparoscopic implantation of a neurostimulator—LION procedure—to the entire superior hypogastric plexus. Results Of the 4 reported patients, 3 are able to partially void or empty their bladder. Conclusions If the presented results could be obtained in further patients and maintained in long-term follow-up, the LION procedure to the superior hypogastric plexus could change the management of bladder function in pati…

Malemedicine.medical_treatmentEndometriosisurologic and male genital diseasesColonic DiseasesPostoperative ComplicationsMedicineLaparoscopyUrinary bladdermedicine.diagnostic_testProstatectomyHypogastric PlexusBladder atoniaEquipment DesignMiddle Agedfemale genital diseases and pregnancy complicationsPain IntractableBladder atonia; LION procedure; Superior hypogastric plexusmedicine.anatomical_structureFemaleSuperior hypogastric plexumedicine.symptomSuperior hypogastric plexusAdultmedicine.medical_specialtyUrinary BladderEndometriosisElectric Stimulation TherapyCauda equineHysterectomyPelvic Painmedicine.nerveSuperior hypogastric plexusHumansUrinary Bladder NeurogenicSpina bifidaProstatectomyHypogastric PlexusHysterectomybusiness.industryPelvic painProstatic Neoplasmsmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaEndometrial NeoplasmsSurgeryUrodynamicsRectal DiseasesLION procedureLaparoscopySurgeryNeurology (clinical)businessGenital Diseases FemaleFollow-Up Studies
researchProduct

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

2016

BACKGROUND Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomiz…

Malemedicine.medical_treatmentIntravesical drug administration030232 urology & nephrologyKaplan-Meier EstimateBCG ConnaughtSettore MED/24 - Urologia0302 clinical medicineMaintenance therapyMedicine610 Medicine & healthhigh gradeAged 80 and overHazard ratioMiddle AgedAdministration IntravesicalTreatment OutcomeOncology030220 oncology & carcinogenesisCohortbladder cancerFemaleImmunotherapyNon muscle invasivemedicine.medical_specialtyrecurrenceUrologyBCG Connaught; BCG Tice; BCG vaccine; bladder cancer; high grade; Immunotherapy; Intravesical drug administration; progression; recurrence; T1G3; Oncology; UrologyT1G3ArticleMaintenance ChemotherapyBCG Connaught03 medical and health sciencesAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]HumansNeoplasm InvasivenessBCG vaccineAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryImmunotherapy ActiveBCG TiceImmunotherapymedicine.diseaseSurgeryUrinary Bladder NeoplasmsDrug EvaluationprogressionNeoplasm GradingbusinessBCG vaccineFollow-Up StudiesBCG Connaught; BCG Tice; BCG vaccine; Immunotherapy; Intravesical drug administration; T1G3; bladder cancer; high grade; progression; recurrenceUrologic Oncology: Seminars and Original Investigations
researchProduct

Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.

2011

Objectives: Nomograms are statistical models designed to maximize predictive accuracy. We have tested the statistical correlation between the predictions of International Bladder Cancer Nomogram Consortium and the clinical outcomes in a multicenter Italian cohort of patients treated with radical cystectomy (RC) and pelvic lymph-nodes dissection. Methods and materials: Two hundred four patients who underwent RC were selected for multiple variable and then enrolled in the study. Patients were tested by the "online tool" based on the nomogram, then stratified and risk grouped for 5-year predicted disease-free survival (pDFS): low risk (67%-100%), intermediate risk (34%-66%), and high risk grou…

Malemedicine.medical_treatmentKaplan-Meier EstimatePostoperative nomogramNomogramCohort StudiesRetrospective StudieArea under curvePostoperative Periodinvasive bladder cancer; Postoperative nomogramAged 80 and overSettore MED/24 - UROLOGIAinvasive bladder cancerMiddle AgedPrognosisOncologyArea Under CurveUrinary Bladder NeoplasmCohortFemaleHumanCohort studyAdultmedicine.medical_specialtyPrognosiUrologyUrologyCystectomyDisease-Free SurvivalCystectomymedicineHumansAgedNeoplasm StagingRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryRetrospective cohort studyNomogrammedicine.diseaseRadical cystectomyNomogramsROC CurveUrinary Bladder NeoplasmsCohort StudieNeoplasm GradingPredictionbusinessStatistical correlationUrologic oncology
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct